Sibylle Loibl, Chief Executive Officer of GBG Forschungs GmbH, shared a post on LinkedIn:
“GBG presentations at the ESMO Congress 2025 in Berlin
The GBG will present data from two of its own studies at this year’s ESMO Congress (October 17–21, 2025, Berlin):
Oral Presentation
‘Durvalumab in Combination with Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC) – Long-term Analysis from the GeparNuevo Trial’
- Sunday, October 19, 2025
- 10:15–11:45 CEST
- Munich Auditorium, CityCube B
- Presented by Sibylle Loibl
Poster Presentation
‘HER2 IHC Status of Primary Breast Cancer Tumor and Brain Metastases in the BMBC Registry’
- Monday, October 20, 2025
- 12:00–12:45 CEST
- Hall 25
- Presented by Elena Laakmann
We look forward to contributing to the scientific discussions at the world’s leading oncology congress and invite you to join these sessions in Berlin.”
More posts featuring Sibylle Loibl.
